The APC Board of Directors has authorized release of a public statement, Understanding Law and Regulation Governing the Compounding of Peptide Products.
A new NCPA survey reveals local pharmacies are struggling to stay afloat after the January 1 implementation of the CMS DIR rule, requiring all pharmacy price concessions (i.e., DIR fees) to be assessed at the point of sale.
The Massachusetts Board of Registration in Pharmacy held a hearing February 28 on proposed new fees for pharmacy licenses in the state.
The Florida Board of Pharmacy Compounding Subcommittee met last week to discuss the state’s USP 797 inspection process.
A couple of years ago, APC released a brief for prescribers on peptide compounding. The title of that brief was “Compounded Peptides: It’s Complicated.” Since the release of that brief, it hasn’t gotten any less complicated.
Long-time APC partner PCCA is our newest Diamond-level Corporate Patron for 2024 and has committed additional funding to sponsor a series APC regional meetings this year.
Alliance for Pharmacy Compounding Statement in Response to FDA Commissioner Califf’s Misstatement Conflating Compounded Drugs and Counterfeit Substances
We presume that the Commissioner’s conflation of legitimate compounded drugs with illicit substances sold direct-to-consumer was inadvertent. Regardless, it requires a correction.
The number of APC Pharmacy-Facility Memberscontinues to grow (and grow and grow). We’ve added 23 since November, bringing the total number to 162.
As you know, New York currently requires pharmacists to directly supervise any pharmacy technicians who are compounding. What you may not know is that bills have been introduced in the state legislature to remove that requirement.